Bioengineered factor Xa as a potential new strategy for hemophilia therapy

Expert Review of Hematology

Volumn 5, Issue 2, 2012, Pages 121-123

  Camire, Rodney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bypass agents; factor Xa; hemophilia; hemostasis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTEIN C; PROTHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; BLOOD CLOTTING FACTOR 5A;

ALLOSTERISM; BIOENGINEERING; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CATALYSIS; CONFORMATIONAL TRANSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; DRUG SAFETY; ENZYME CONFORMATION; FIBRIN DEPOSITION; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; X CHROMOSOME; ANIMAL; DISEASE MODEL; DOG; EDITORIAL; GENETICS; METABOLISM; MOUSE; PROTEIN ENGINEERING;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; FACTOR VA; FACTOR XA; HEMOPHILIA A; HUMANS; MICE; PROTEIN ENGINEERING;

EID: 84864111891     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.13     Document Type: Review

References (21)

1. Roberts HR, Ma AD. Overview of inherited hemorrhagic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice (5Thedition). Colman RW, Marder VJ, Clowes AW, Gerorge JN, Goldhaber SZ (Eds). Lippincott Williams & Wilkins, PA, USA, 877-885 (2006).
2. Mann KG, Nesheim ME, Church WR, Haley PE, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76(1), 1-16 (1990).
3. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 14(Suppl. 3), 10-18 (2008).
4. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 10(Suppl. 2), 3-9 (2004).
5. Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu. Rev. Med. 59, 29-41 (2008).
6. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 15(1), 3-10 (2009).
7. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem. Pharmacol. 82(2), 91-98 (2011).
8. Schlachterman A, Schuettrumpf J, Liu JH et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3(12), 2730-2737 (2005).
9. Butenas S, Orfeo T, Kalafatis M, Mann KG. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J. Thromb. Haemost. 4(11), 2411-2416 (2006).
10. Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat. Biotechnol. 18(3), 289-295 (2000).
11. Prasad S, Lillicrap D, Labelle A et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111(2), 672-679 (2008).
12. Waters EK, Genga RM, Schwartz MC et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 117(20), 5514-5522 (2011).
13. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br. J. Haematol. 69(4), 491-497 (1988).
14. Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283(27), 18627-18635 (2008).
15. Ivanciu L, Toso R, Margaritis P et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29(11), 1028-1033 (2011).
16. Himmelspach M, Richter G, Muhr E et al. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo. Thromb. Haemost. 88(6), 1003-1011 (2002).
17. Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang. 85(4), 290-299 (2003).
18. Wolf DL, Lin PH, Hollenbach S et al. Procoagulant activity of reversibly acylated human factor Xa. Blood 86(11), 4153-4157 (1995).
19. Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, Le Bonniec BF. Thrombin-activable factor X reestablishes an intrinsic amplification in tenase-deficient plasmas. J. Biol. Chem. 280(50), 41352-41359 (2005).
20. Khan AM, James MNG. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Prot. Sci. 7(4), 815-836 (1998).
21. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 117(1), 290-298 (2011).